Understanding Asthma Pathogenesis: Mechanisms, Triggers, and Therapeutic Advances

All three hit the same underlying vulnerability: airway hyperresponsiveness (AHR). In asthmatic lungs, bronchial smooth muscle has a hair-trigger sensitivity that healthy lungs don't have. Cold air: breathing cold, dry air rapidly causes the airway lining to lose heat and moisture. This triggers mast cells to release histamine and leukotrienes — exactly the same chemicals released during an allergen response — causing bronchoconstriction within minutes. Exercise: increased breathing rate draws in more air faster, which dries and cools the airways. Post-exercise, when breathing slows, the airways experience rapid temperature/moisture swings. This is 'exercise-induced bronchoconstriction' (EIB) — affects up to 40% of asthma patients and up to 90% in cold-air sports. Viral infections (rhinovirus, RSV): viruses directly infect airway epithelium, releasing chemokines that amplify the existing Th2 inflammatory response. Even a mild cold that a non-asthmatic shrugs off can trigger an asthmatic to have a severe exacerbation needing oral steroids. This is why annual flu vaccination is so important — preventing viral infection prevents one of the biggest exacerbation triggers.

This distinction has become clinically crucial because treatment response differs significantly. Eosinophilic asthma (roughly 50–60% of moderate-severe asthma): driven by Th2 immunity — mast cells, IgE, IL-4/IL-5/IL-13 cytokines, and high blood/sputum eosinophil counts. This type responds very well to inhaled corticosteroids (ICS) and, for severe cases, to biologic therapies (mepolizumab: anti-IL-5; benralizumab: anti-IL-5 receptor; dupilumab: anti-IL-4/13 receptor). Blood eosinophil count above 300 cells/µL is a reasonable threshold for biologic trial. Non-eosinophilic (neutrophilic) asthma: driven by innate immunity, often triggered by pollution, smoking, obesity, or bacterial infection. ICS are less effective and may even increase infection risk. Macrolide antibiotics (azithromycin) have some evidence in this phenotype. Why does this matter for you as a patient? If your asthma remains poorly controlled despite high-dose ICS + LABA (a standard step-up), ask your pulmonologist about eosinophil testing and whether a biologic is indicated. In India, mepolizumab (Nucala) and omalizumab (Xolair) are available at major centres (AIIMS, PGI, Tata Memorial, Apollo) under DCGI approval, typically ₹25,000–80,000/dose depending on body weight.

Not definitely — but your risk is meaningfully elevated. Asthma heritability is around 60–70% (twin studies). The genes involved — ADAM33 (airway remodeling), IL-4 and IL-13 genes (IgE production), and over 50 loci identified in genome-wide association studies — create a susceptibility, not a destiny. What typically converts susceptibility into disease: (1) early-life allergen exposure — children who grow up with intense dust mite or pet dander exposure in genetically susceptible homes have higher rates; (2) viral lower respiratory infections before age 3 (RSV, rhinovirus) — these appear to 'prime' the immune system toward the Th2 pathway in susceptible children; (3) air pollution — both outdoor PM2.5 (Delhi, Mumbai rank among the world's most polluted cities) and indoor biomass-smoke exposure. If asthma runs in your family, the practical steps are: allergen-proof mattress covers from birth for new babies, no indoor smoking ever, flu shots every year, and watching for wheeze or recurrent 'chest colds' in children — those are worth flagging to a paediatrician early rather than waiting.

Biologics are injectable monoclonal antibodies that target specific inflammatory proteins in the asthma cascade — unlike inhalers that broadly suppress inflammation, biologics are precision medicine. The main options approved for severe asthma: (1) Omalizumab (Xolair): anti-IgE antibody — blocks IgE from binding mast cells and basophils; indicated for severe allergic asthma with high IgE levels; reduces exacerbations by 25–50%; (2) Mepolizumab (Nucala), benralizumab (Fasenra): anti-IL-5 pathway; indicated for severe eosinophilic asthma (blood eosinophils ≥300/µL); reduces severe exacerbations by 50–70%; (3) Dupilumab (Dupixent): anti-IL-4Rα — blocks both IL-4 and IL-13; also indicated for atopic dermatitis and eosinophilic esophagitis. Who qualifies: severe asthma not controlled despite high-dose ICS + LABA; typically needs confirmation of the asthma phenotype (eosinophil count, IgE levels, allergy skin-prick tests). In India, these are available at AIIMS Delhi, PGI Chandigarh, and major Apollo, Fortis, and Manipal Hospital respiratory centres. Cost is the main barrier: ₹20,000–80,000 per injection (monthly to 2-monthly dosing). Some state government programmes and Ayushman Bharat covers biologic therapy for eligible rare respiratory disease cases.